What is esomeprazole and Levosulpiride used for?
Pharmaceutical Product Monograph: Esomeprazole & Levosulpiride FDC
In the pharmaceutical industry, the combination of Esomeprazole and Levosulpiride is a high-demand Fixed-Dose Combination (FDC). As a pharmacist and manufacturer, I classify this as a “Dual-Action Gastro-Prokinetic.” It is technically superior to simple antacids because it treats both the chemical (acid) and mechanical (motility) causes of digestive distress.
At your WHO-GMP facility in Mumbai, this Sustained-Release (SR) capsule is a “best-seller” for Gastroenterology portfolios, particularly for patients with “Functional Dyspepsia” who do not respond to PPIs alone.
Therapeutic Profile: Primary Indications
This combination is indicated for complex acid-peptic disorders where stomach emptying is delayed.
| Component | Technical Role | Clinical Indication |
| Esomeprazole (40 mg) | PPI (Proton Pump Inhibitor) | GERD, Heartburn, Gastric Ulcers, and Zollinger-Ellison Syndrome. |
| Levosulpiride (75 mg SR) | Prokinetic / $D_2$ Antagonist | Functional Dyspepsia, Diabetic Gastroparesis, and Irritable Bowel Syndrome (IBS). |
Combined Use: It is specifically used for Gastroesophageal Reflux Disease (GERD) that is resistant to standard therapy, as well as chronic bloating and “fullness” after meals.
Mechanism: The “Chemical-Mechanical” Synergy
The two drugs work in tandem to normalize the environment of the upper GI tract:
Acid Suppression (Esomeprazole): It technically inhibits the $H^+/K^+$-ATPase enzyme system (the “proton pump”) at the secretory surface of the gastric parietal cell. This provides long-lasting reduction of gastric acid.
Motility Enhancement (Levosulpiride): It is a selective antagonist of central and peripheral dopamine $D_2$ receptors. By blocking dopamine, it increases the release of acetylcholine.
The Result: This technically increases the tone of the Lower Esophageal Sphincter (preventing acid from rising) and speeds up Gastric Emptying (moving food out of the stomach faster).
The Pharmacist’s “Technical Warning”
The “Morning” Rule: To ensure maximum bioavailability, these capsules must be taken on an empty stomach, preferably 30–60 minutes before breakfast.
Extrapyramidal Symptoms (EPS): Because Levosulpiride crosses the blood-brain barrier, it can technically cause tremors or “restless legs” in some patients. This is rare but must be monitored.
Hormonal Shifts: Levosulpiride can increase Prolactin levels, which may lead to breast tenderness or menstrual irregularities in some users.
Bone Health: Long-term use of Esomeprazole (over 1 year) can technically reduce calcium absorption, increasing the risk of fractures in geriatric patients.
The Manufacturer’s Perspective: Technical & Export
From the CEO’s desk at Healthy Life Pharma / Healthy Inc:
The “SR” Technology: At our Mumbai plant, we focus on the Sustained Release (SR) formulation of Levosulpiride. This is technically superior because it provides a steady 24-hour prokinetic effect with a single daily dose, significantly improving patient compliance.
The “Refractory GERD” Market: On your digital marketplace, position this FDC for patients who “fail” on Omeperazole or Pantoprazole alone. This “Specialized GI” niche is highly profitable for B2B export to private hospital chains.
Stability & Packaging: Esomeprazole is highly acid-labile. We ensure our capsules use Enteric-Coated (EC) Pellets. Use Alu-Alu blistering to prevent moisture ingress, which can degrade the pellets and lead to “Product Inefficacy” claims in tropical export zones.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Esomeprazole 40 mg + Levosulpiride 75 mg SR to support your registration in international B2B tenders.